BiotechTube

Raltegravir (Isentress®)

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HIV

Conditions

HIV, AIDS

Trial Timeline

Aug 1, 2008 → Sep 1, 2009

NCT ID
NCT00774683

About Raltegravir (Isentress®)

Raltegravir (Isentress®) is a pre-clinical stage product being developed by Merck for HIV. The current trial status is completed. This product is registered under clinical trial identifier NCT00774683. Target conditions include HIV, AIDS.

What happened to similar drugs?

20 of 20 similar drugs in HIV were approved

Approved (20) Terminated (1) Active (0)
✅Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABVCiplaApproved
✅Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved
✅Lopinavir/RitonavirAbbVieApproved
✅Ritonavir boosted Atazanavir + Raltegravir + TDF/FTC (or 3TC)MerckApproved
✅RaltegravirMerckApproved
✅raltegravirMerckApproved
✅Kaletra + Isentress + Pre-study antiretroviral regimenMerckApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00774683Pre-clinicalCompleted

Competing Products

20 competing products in HIV

See all competitors
ProductCompanyStageHype Score
DOR/ISLMerckPhase 2
35
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice dailyShionogiPhase 3
40
GSK1265744 10 mg oral solution + GSK1265744 5 mg tablet + GSK1265744 5 mg tabletShionogiPhase 1
29
GW810781ShionogiPhase 2
35
Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABVCiplaApproved
43
Antiretroviral Therapy (ART) + Baricitinib (LY3009104) 2 mgEli LillyPhase 2
42
Epoetin alfaJohnson & JohnsonPre-clinical
26
LevofloxacinJohnson & JohnsonPhase 1
29
SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；PlaceboJiangsu Hengrui MedicinePhase 1
29
ABBV-181 + PlaceboAbbViePhase 1
29
ABBV-382 + ABBV-382 + Placebo for ABBV-382AbbViePhase 1
29
Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved
43
lopinavir/ritonavir + lamivudineAbbViePre-clinical
26
Lopinavir/RitonavirAbbVieApproved
43
Budigalimab + Placebo + Budigalimab + PlaceboAbbViePhase 1
29
Budigalimab + Placebo for Budigalimab + ABBV-382 + Placebo for ABBV-382 + BudigalimabAbbViePhase 2
27
CVC 150 mg + CVC 300 mgAbbViePhase 2
35
Rosuvastatin 10 mg. daily for 96 weeks + PlaceboAstraZenecaPhase 2
35
Raltegravir + Placebo + Current ARTMerckPhase 3
40
Indinavir sulfate + Lamivudine + ZidovudineMerckPhase 3
40